Prana AGM Investor Conference Call
Prana invites investors unable to attend the Company’s Annual General Meeting to participate via teleconference.
Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA
PBT434 prevents alpha-synuclein aggregation, preserves neurons, reduces glial cell inclusions and slows motor dysfunction in an animal model of Multiple System Atrophy
Link to XBRL Interactive Data 30 June 2018
PBT434 data to be presented at the International Congress of Parkinson’s Disease and Movement Disorders
Prana’s PBT434 prevents neuronal loss in a new model of neurodegeneration
First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases
Prana Biotechnology is pleased to announce the first cohort of volunteers in its Phase I clinical trial have been administered PBT434, an experimental drug under investigation for the treatment of Parkinsonian diseases.
Prana Biotechnology Investor Presentation
Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases
Prana Biotechnology is pleased to announce it has received ethics committee approval and has commenced recruitment for its Phase I Clinical trial evaluating the safety, tolerability and pharmacokinetics of the Company’s lead drug candidate, PBT434, in healthy volunteers.
Dr David Stamler China Investor & Partnering Symposium Webcast
Prana to Present at the B. Riley FBR China Healthcare Investment & Partnering Symposium in Hangzhou, China
Dr. David Stamler will be presenting at the China Healthcare Investment & Partnering Symposium on Saturday 17 March 2018 at 9.30am China Standard Time.